Core Viewpoint - The company maintains its revenue forecasts for fiscal years 2026 and 2027, while adjusting net profit estimates significantly upward due to cost control measures [1] Group 1: Financial Performance - For the first half of fiscal year 2026, the company's revenue reached 360 million yuan, reflecting an 8.7% year-on-year growth, which aligns with previous expectations [2] - The net loss for the same period narrowed significantly by approximately 72% compared to the previous year [2] - The adjusted net profit forecasts for fiscal years 2026 and 2027 are raised to 410,000 yuan and 5.457 million yuan, respectively, from previous estimates of -45.69 million yuan and 4.11 million yuan [1] Group 2: Business Segments and Growth Drivers - The revenue from the big data platform and solutions increased by 14.6% year-on-year to 153 million yuan, driven by policy support and expanded business opportunities [3] - The health management platform and solutions saw a 30.3% year-on-year revenue growth to 66.67 million yuan, with significant participation in the Huiminbao project across 5 provinces and 13 cities [3] - The life sciences solutions revenue slightly declined by 4.4% to 138 million yuan, as the company integrates AI technology into the entire clinical trial process [3] Group 3: Operational Efficiency - The overall gross margin improved by 1.8 percentage points to 37.4%, with the gross margin for the big data platform and solutions increasing by 5.1 percentage points to 42.5% [4] - The company reduced its net loss to 15.76 million yuan, continuing the trend of narrowing losses [4] - Operating cash flow net outflow decreased by 56% year-on-year due to enhanced cash management and efficiency [4]
中金：维持医渡科技跑赢行业评级 目标价6.8港元